Know Cancer

forgot password

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer

Phase 2
18 Years
Not Enrolling
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer

The rationale of this study is to combine two distinct kinase inhibitors to evaluate
synergistic inhibition of angiogenesis and epidermal growth factor receptor (EGFR)
signaling. Erlotinib is a oral tyrosine kinase inhibitor that targets EGFR. Sorafenib is a
oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor
(VEGFR), platelet derived growth factor receptor beta, Raf-1, Flt-3, and C-kit. These agents
also do not exhibit overlapping adverse event profiles which provided additional support for
studying this combination therapy.

Inclusion Criteria:

- Histologically confirmed locally advanced or metastatic NSCLC (unresectable stage
IIIB or stage IV). Eligible histologies include adenocarcinoma and squamous cell
carcinoma. Patients with recurrent disease after treatment for localized NSCLC are
also eligible. Cytologic specimens obtained by brushings, washings, or needle
aspiration are acceptable.

- At least one lesion that can be accurately measured in at least one dimension
(longest diameter to be recorded) as >= 20 mm with conventional techniques, or as >=
10 mm with spiral computerized tomography (CT) scan according to the Response
Evaluation Criteria in Solid Tumors (RECIST).

- Failure of at least one, and no more than two prior cytotoxic chemotherapy regimens
for advanced disease (either due to progressive disease or toxicity).

- Recovery from any toxic effects of prior therapy to <= grade 1.

- Completion of radiation therapy at least 28 days prior to the start of study
treatment (not including palliative local radiation). Previously irradiated lesions
in the advanced setting cannot be included as target lesions unless clear tumor
progression has been observed since the end of radiation.

- An ECOG performance status of 0-2.

- Absolute neutrophil count (ANC) >= 1,500, platelets >= 75,000.

- Hemoglobin >= 9 g/dL (within 7 days prior to study treatment).

- International normalized ratio (INR) <= 1.5 or prothrombin time (PT)/partial
thromboplastin time (PTT) within normal limits (WNL) of the institution

- Serum creatinine <= 1.5 x institutional upper limit of normal (ULN) within 7 days
prior to study treatment.

- Transaminases <= 3 x institutional ULN

- Agreement of female patients of childbearing potential and male patients who have
partners of childbearing potential to use an effective form of contraception to
prevent pregnancy during treatment, and for a minimum of 90 days thereafter.

- Patients who have treated brain metastases >= 4 weeks out (with surgery and/or
radiation therapy) and no evidence of CNS progression.

Exclusion Criteria:

- Past or current history of neoplasm (other than the entry diagnosis), with the
exception of treated non-melanoma skin cancer or carcinoma in-situ of the cervix, or
other cancers cured by local therapy alone, and a disease-free survival (DFS) >= 3

- Patients who have mixed tumors with small-cell elements are ineligible.

- Pregnancy or lactation.

- Prior treatment with EGFR TKIs or VEGFR TKIs for NSCLC. [NOTE: prior cetuximab and/or
bevacizumab use is permitted].

- Significant cardiac disease within 90 days of starting study treatment

- Myocardial infarction within 6 months prior to initiation of study treatment.

- Cardiomegaly on chest imaging or ventricular hypertrophy on electrocardiogram (ECG)

- Poorly controlled hypertension

- Unstable angina (anginal symptoms at rest).

- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

- Presence of cardiac disease that, in the opinion of the investigator, increases the
risk of ventricular arrhythmia.

- A serious underlying medical condition that would impair the ability of the patient
to receive protocol treatment.

- A major surgical procedure, open biopsy, or significant traumatic injury within 28
days of beginning treatment, or anticipation of the need for major surgery during the
course of the study.

- Stroke or transient ischemic attack (TIA) within the past 6 months.

- Any prior history of hypertensive crisis or hypertensive encephalopathy.

- Pulmonary hemorrhage/bleeding event >= grade 2 within 28 days of study treatment.

- Any other non-pulmonary hemorrhage/bleeding event >= grade 3 within 28 days of study

- Evidence or history of bleeding diathesis or coagulopathy.

- Serious non-healing wound, ulcer, or bone fracture.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Overall Objective Response Rate (ORR)

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

David Spigel, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Institutional Review Board

Study ID:




Start Date:

February 2008

Completion Date:

February 2009

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Advanced
  • Sorafenib
  • Erlotinib
  • Double-blind
  • Placebo-controlled
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Florida Cancer Specialists Fort Myers, Florida  33901
Northeast Georgia Medical Center Gainesville, Georgia  30501
South Carolina Oncology Associates, PA Columbia, South Carolina  29210
Family Cancer Center Collierville, Tennessee  38017
Virginia Cancer Institute Richmond, Virginia  23230
Methodist Cancer Center Omaha, Nebraska  68114
Center for Cancer and Blood Disorders Bethesda, Maryland  20817
Cancer Care of Western North Carolina Asheville, North Carolina  28801
Grand Rapids Clinical Oncology Program Grand Rapids, Michigan  49503
Kansas City Cancer Centers Lenexa, Kansas  
Tennessee Oncology, PLLC Clarksville, Tennessee  37043
Coastal Bend Cancer Center Corpus Christi, Texas  78404
Wellstar Cancer Research Marietta, Georgia  30060
Oncology Hematology Care Cincinnati, Ohio  45242
Chattanooga Oncology Hematology Associates Chattanooga, Tennessee  37404
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center Columbus, Ohio  43219